Geode Capital Management LLC Buys 106,807 Shares of ACADIA Pharmaceuticals Inc. $ACAD

Posted by Geri Gentry on Jun 8th, 2026

Geode Capital Management LLC boosted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 3.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,239,451 shares of the biopharmaceutical company’s stock after buying an additional 106,807 shares during the quarter. Geode Capital Management LLC’s holdings in ACADIA Pharmaceuticals were worth $86,539,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Farther Finance Advisors LLC boosted its stake in ACADIA Pharmaceuticals by 67.5% in the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 386 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in ACADIA Pharmaceuticals by 107.0% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 885 shares in the last quarter. Leonteq Securities AG acquired a new stake in ACADIA Pharmaceuticals in the 4th quarter valued at $52,000. iSAM Funds UK Ltd acquired a new stake in ACADIA Pharmaceuticals in the 3rd quarter valued at $93,000. Finally, PNC Financial Services Group Inc. boosted its stake in ACADIA Pharmaceuticals by 11.2% in the 3rd quarter. PNC Financial Services Group Inc. now owns 5,323 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 534 shares in the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on ACAD. Stifel Nicolaus decreased their price target on ACADIA Pharmaceuticals from $25.00 to $24.00 and set a “hold” rating on the stock in a research note on Thursday, February 26th. Citigroup decreased their price target on ACADIA Pharmaceuticals from $33.00 to $32.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Weiss Ratings downgraded ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 1st. Bank of America upgraded ACADIA Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $29.00 price objective for the company in a research report on Wednesday, March 25th. Finally, JPMorgan Chase & Co. lifted their price objective on ACADIA Pharmaceuticals from $31.00 to $34.00 and gave the company an “overweight” rating in a research report on Wednesday, March 4th. Eleven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.63.

View Our Latest Report on ACAD

ACADIA Pharmaceuticals Price Performance

ACAD stock opened at $21.56 on Monday. The company has a market cap of $3.69 billion, a P/E ratio of 9.80, a PEG ratio of 27.07 and a beta of 0.83. ACADIA Pharmaceuticals Inc. has a twelve month low of $19.69 and a twelve month high of $28.35. The business has a fifty day moving average of $21.77 and a 200-day moving average of $23.74.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The firm had revenue of $268.10 million for the quarter, compared to the consensus estimate of $280.25 million. ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The company’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.11 EPS. As a group, equities research analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.37 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Mark C. Schneyer sold 3,506 shares of the business’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $21.79, for a total transaction of $76,395.74. Following the completion of the sale, the executive vice president owned 66,145 shares in the company, valued at $1,441,299.55. The trade was a 5.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider James Kihara sold 5,401 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total value of $114,393.18. Following the sale, the insider owned 24,509 shares of the company’s stock, valued at approximately $519,100.62. The trade was a 18.06% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 13,978 shares of company stock valued at $302,819. 26.20% of the stock is currently owned by corporate insiders.

About ACADIA Pharmaceuticals

(Free Report)

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.